Association of Coagulopathy and Inflammatory Biomarkers with Severity in SARS-CoV-2-Infected Individuals of the Al-Qunfudhah Region of Saudi Arabia

Izhari, Mohammad Asrar; Hadadi, Mansoor A. A.; Alharbi, Raed A.; Gosady, Ahmed R. A.; Sindi, Abdulmajeed Abdulghani A.; Dardari, Daifallah M. M.; Alotaibi, Foton E.; Klufah, Faisal; Albanghali, Mohammad A; Alharbi, Tahani H

doi:10.3390/healthcare12070729

Cited by 1 publication

(1 citation statement)

References 73 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our study, we excluded patients with COVID-19 to match the inclusion criteria of a previous similar study by Han,et al [6]. This was also because COVID-19 has been linked to thrombocytopenia of varying degrees, as reported in previous studies, case reports, and case series [19,[31][32][33][34][35][36][37][38]. Thus, we wanted to exclude this condition as a potential confounding factor.…”

Section: Discussionmentioning

confidence: 99%

Linezolid-Associated Thrombocytopenia: Assessment of Risk Factors in Patients without Hemato-Oncologic Diseases

Thabit,

Alghamdi,

Alsaeed

et al. 2024

JCM

View full text Add to dashboard Cite

Background: Linezolid is used for Gram-positive bacterial infections. Thrombocytopenia is one of its main adverse effects resulting from myelosuppression. Several studies have assessed risk factors that may increase the risk of this adverse effect. However, most studies included patients with hemato-oncologic diseases, which may confound such assessments. This study aimed to investigate risk factors for linezolid-associated thrombocytopenia in patients without hemato-oncologic diseases. Methods: This was a multicenter retrospective case-control study of adult patients treated with linezolid twice daily for ≥3 days. Patients with hemato-oncologic diseases, active dengue fever, active COVID-19, baseline platelet count <100 × 103/mm3, concurrent therapy with trimethoprim/sulfamethoxazole or valproic acid, and a recent platelet transfusion within 7 days were excluded. Thrombocytopenia was defined as a drop in platelet count below 100 × 103/mm3. Results: Out of 158 evaluated patients, 33 developed thrombocytopenia, indicating an incidence rate of 20.9%. Of all the risk factors assessed, creatinine clearance of <60 mL/min and bacteremia/infective endocarditis were significantly associated with linezolid-associated thrombocytopenia (adjusted odds ratios, 3.25 and 5.95; 95% CI 1.12–9.45 and 1.23–28.66; p = 0.031 and 0.026, respectively). End of therapy platelet counts were significantly lower in the cases than in the controls (79 vs. 243 × 103/mm3; p < 0.001). Similarly, the percentage of platelet count change was significantly different (−55.1% vs. −10.2%; p < 0.001). Conclusions: In our study, the incidence rate of linezolid-associated thrombocytopenia was 20.9%, and we found that patients with renal impairment and bacteremia may need close monitoring of platelet counts. Prospective studies are warranted to evaluate the potential need for renal dose adjustment.

show abstract